Announced Sat, 27 Jun · 14:36 IST

Investor presentation with USFDA update and five year growth projections

Analyst Day Multiyear TargetsOrder Pipeline DisclosedMgmt Guided Margin ImprovementInvestor Communications View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+6.5%1-day move

₹30.52

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————+6.5+6.7+6.5+6.7+10.7+20.4+34.7———

Up moveDown movePending

AI summary

Veerhealth Care filed its investor presentation with BSE. Key highlights: USFDA clearance received in June 2025 for Drug (OTC) product exports. FY26 revenue rose to 32.48 cr from 24.15 cr YoY, with profit improving to 0.91 cr. Company projects revenue of 102.98 cr and 152.47 cr over coming years alongside rising profits. Recently onboarded a leading 125-year-old FMCG group in personal and household care. Added Veer Plast division for backward integration. Targets to become a leading small-cap global exporter over five years.

Likely market impact

USFDA clearance, FMCG onboarding, and steep multi-year revenue projections are positive for sentiment, though execution and small-cap risks remain.